Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15427711 | 0.75 | PTK2 (0.44) | ALDH1A1CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL24701899 | 0.74 | TDP1 (0.39) | ALDH1A1CYP3A4MEN1KMT2APDK2 | |
| SCHEMBL807467 | 0.73 | ALDH1A1 (0.40) | ALDH1A1CASP1CYP3A4TSHRPDE10A | |
| SCHEMBL14439097 | 0.73 | ALDH1A1 (0.40) | ALDH1A1CASP1CYP3A4TSHRPDE10A | |
| SCHEMBL16812209 | 0.70 | ALDH1A1 (0.37) | ALDH1A1CASP1CYP3A4TSHRPDE10A | |
| SCHEMBL6742481 | 0.70 | MEN1 (0.54) | ALDH1A1CASP1CYP3A4TSHRMEN1 | |
| SCHEMBL17528668 | 0.69 | PDK2 (0.42) | ALDH1A1CASP1CYP3A4TSHRPDE10A | |
| SCHEMBL16905573 | 0.68 | PGR (0.38) | ALDH1A1BACE1PDK2 | |
| SCHEMBL30648685 | 0.68 | CA9 (0.38) | ALDH1A1MEN1KMT2ABACE1MAPT | |
| SCHEMBL26640593 | 0.68 | CA9 (0.38) | ALDH1A1MEN1KMT2ABACE1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| EP-1228055-A1 | DIHYDROAMINOBENZO[B]- AND [C]FURANS AS RETINOID-LIKE AGENTS | Allergan Sales, Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| WO-2001012618-A1 | DIHYDROAMINOBENZO[B]- AND [C]FURANS AS RETINOID-LIKE AGENTS | ALLERGAN SALES, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| US-6093838-A | FOR TREATING SKIN-RELATED DISEASES, INCLUDING ACTINIC KERATOSES, ARSENIC KERATOSES, ECZEMA | ALLERGAN SALES, INC. (US) | 2000-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | ALDH1A1 3632/4885CASP1 2578/4885CYP3A4 4586/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | ALDH1A1 3632/4885CASP1 2578/4885CYP3A4 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.